Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 310 shares, an increase of 3,344.4% from the May 14th total of 9 shares. Based on an average trading volume of 2,834 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Enzon Pharmaceuticals Stock Performance

Shares of ENZN stock remained flat at $5.75 during mid-day trading on Tuesday. 1,857 shares of the stock were exchanged, compared to its average volume of 1,920. Enzon Pharmaceuticals has a 12-month low of $1.50 and a 12-month high of $12.99. The firm’s 50 day moving average price is $6.03 and its 200 day moving average price is $5.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last issued its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The firm had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.